GRN

Montrose Regional Health Partners with Guardian Research Network for Research

Retrieved on: 
Thursday, November 16, 2023
Microsoft Partner Network, Clinical trial, Health, Research, Patient, Organization, Partnership, MRH, GRN, Pharmaceutical industry, Uncompahgre Valley

SPARTANBURG, S.C., Nov. 16, 2023 /PRNewswire/ -- Guardian Research Network (GRN) announced today that Montrose Regional Health (MRH), the leading healthcare facility in Colorado's Uncompahgre Valley, has joined its nationwide healthcare research consortium. The new alliance lays the foundation for MRH's research by introducing opportunities for clinical trials in multiple care specialties while supporting GRN in continuing to drive clinical trial participation nationally.

Key Points: 
  • SPARTANBURG, S.C., Nov. 16, 2023 /PRNewswire/ -- Guardian Research Network (GRN) announced today that Montrose Regional Health (MRH), the leading healthcare facility in Colorado's Uncompahgre Valley, has joined its nationwide healthcare research consortium.
  • Montrose Regional Health's core values include always pursuing the best outcomes for patients, making the partnership with GRN the logical next step for the hospital."
  • Representing millions of patients across the country, GRN focuses on advancing healthcare data technology, clinical research trials, and real-world data science.
  • Through the dynamic national database, GRN focuses on advancing healthcare data technology, clinical research trials and real-world data science.

AviadoBio Announces FDA IND Clearance and Fast Track Designation for AVB-101 for the Treatment of Frontotemporal Dementia with Progranulin (GRN) Mutations

Retrieved on: 
Monday, November 6, 2023
Biotechnology, Pharmaceutical, Oncology, General Health, Health, FDA, Genetics, Clinical Trials, GRN, IND, Autosome, AAV, Food, Genetic, European Commission, Fast Track, Prevalence, Investigational New Drug, EC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Apathy, Personality, Dementia, Civil service commission, Abnormal psychology, Frontotemporal dementia, Gene, Brain, Safety, Patient, Death, FTD, Granulin, Pharmaceutical industry

In addition, the FDA has granted Fast Track designation to AVB-101 for the treatment of FTD-GRN to slow disease progression.

Key Points: 
  • In addition, the FDA has granted Fast Track designation to AVB-101 for the treatment of FTD-GRN to slow disease progression.
  • Both the U.S. FDA and the European Commission (EC) granted orphan designation to AVB-101 for the treatment of FTD in 2022.
  • “The IND clearance and Fast Track designation of AVB-101 are important milestones for the FTD community and for our company.
  • Sadly, there are currently no disease-modifying therapies approved for the treatment of people living with frontotemporal dementia with progranulin mutations.

EQS-News: Greenalia and P2X-Europe request their project Breogan, a game-changing PtL project producing CO2-neutral eFuels and green hydrogen in Galicia, to be classified a Priority Business Initiative

Retrieved on: 
Thursday, October 26, 2023
GRN, Innovation, R group, Structural adjustment, PTL, News, Aviation, Environment, Power, Transport, Ecosystem, Employment, Partnership, CO2, H&R, PBI, Renewable energy, Xunta de Galicia

Greenalia and P2X-Europe request their project Breogan, a game-changing PtL project producing CO2-neutral eFuels and green hydrogen in Galicia, to be classified a Priority Business Initiative (news with additional features)

Key Points: 
  • Greenalia and P2X-Europe request their project Breogan, a game-changing PtL project producing CO2-neutral eFuels and green hydrogen in Galicia, to be classified a Priority Business Initiative (news with additional features)
    The issuer is solely responsible for the content of this announcement.
  • This CO2-neutral project seeks to reduce greenhouse gas emissions by up to 95% and replace conventional fossil crudes with green hydrogen and net-zero carbon synthetic products, including eSAF, eDiesel, and specialty chemicals.
  • By integrating biogenic carbon and green hydrogen from renewable sources, the project paves the way to gradually replace conventional fossil crudes in key sectors.
  • The production of green hydrogen, synthetic hydrocarbons, and eFuels is a significant step toward strategic energy autonomy for Galicia, Spain, and Europe as a whole.

AviadoBio Announces Presentation of Promising Preclinical Safety and Biodistribution Data of its Gene Therapy Candidate AVB-101 for FTD-GRN at the Annual European Society of Gene and Cell Therapy Congress

Retrieved on: 
Tuesday, October 24, 2023
Health, Genetics, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Primate, VGS, GRN, AAV, Neuron, CSF, Congress, Mortality, Vector, CNS, Cerebrospinal fluid, Cell, Gene, Central nervous system, Frontotemporal dementia, ESGCT, Thalamus, Brain, European Society of Gene and Cell Therapy, Patient, FTD, Granulin, Vaccine, Medical imaging, Medical device

AviadoBio , a pioneering gene therapy company dedicated to developing and delivering potentially transformative medicines for neurodegenerative disorders, announced today the presentation of preclinical safety and biodistribution data on AVB-101 at the 30th annual European Society of Gene and Cell Therapy (ESGCT) Congress in Brussels.

Key Points: 
  • AviadoBio , a pioneering gene therapy company dedicated to developing and delivering potentially transformative medicines for neurodegenerative disorders, announced today the presentation of preclinical safety and biodistribution data on AVB-101 at the 30th annual European Society of Gene and Cell Therapy (ESGCT) Congress in Brussels.
  • AVB-101 is an investigational, adeno-associated virus (AAV) gene therapy in development for patients with frontotemporal dementia (FTD) with disease-causing mutations in the GRN gene, known as FTD-GRN.
  • “We are excited to present at ESGCT our preclinical data on a novel gene therapy for people with FTD-GRN.
  • Infusion of AVB-101, containing the GRN gene, directly into the thalamus boosts progranulin protein production and secretion into the cortex.

AviadoBio Announces Initiation of Phase 1/2 Clinical Trial, ASPIRE-FTD, Evaluating AVB-101 in People with Frontotemporal Dementia with GRN Mutations

Retrieved on: 
Tuesday, October 10, 2023
Mental Health, Research, Neurology, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Trial of the century, Brain, Cell, Gene, Safety, GRN, Anatomy, Primate, Frontotemporal dementia, Clinical trial, FTD, ESGCT, European Society of Gene and Cell Therapy, Granulin, Patient, Thalamus, Vaccine

ASPIRE-FTD is an open-label, multi-center study designed to evaluate the safety and preliminary efficacy of AVB-101 in patients with FTD-GRN.

Key Points: 
  • ASPIRE-FTD is an open-label, multi-center study designed to evaluate the safety and preliminary efficacy of AVB-101 in patients with FTD-GRN.
  • “FTD is a devastating form of early-onset dementia and there are currently no disease-modifying treatments available,” said Lisa Deschamps, Chief Executive Officer.
  • People with FTD who have disease-causing GRN mutations produce a reduced amount of progranulin protein.
  • AVB-101 is delivered using a minimally-invasive, stereotactic neurosurgical procedure directly to the part of the brain called the thalamus.

Clemson Rural Health Joins Forces with Guardian Research Network to Improve Community Health

Retrieved on: 
Tuesday, October 3, 2023
Database, Partnership, EMR, GRN, Quality of life, Research, CRH, Doctor of Philosophy, Clemson University, Patient, Clemson, Mortality, Health, Rural area, Nursing, Pharmaceutical industry

SPARTANBURG, S.C., Oct. 3, 2023 /PRNewswire/ -- Guardian Research Network (GRN) announces that Clemson Rural Health (CRH), a Clemson University institution dedicated to statewide rural health services initiatives, has joined its nationwide healthcare research consortium. This new partnership will fuel CRH's mission to transform health outcomes in rural communities by conducting and facilitating clinical trials in historically underserved regions. GRN's expansive healthcare database will help CRH bolster community health efforts to reduce premature mortality, decrease preventable hospitalizations and improve overall quality of life for local South Carolina patients.

Key Points: 
  • SPARTANBURG, S.C., Oct. 3, 2023 /PRNewswire/ -- Guardian Research Network (GRN) announces that Clemson Rural Health (CRH), a Clemson University institution dedicated to statewide rural health services initiatives, has joined its nationwide healthcare research consortium.
  • "Clinical trials are critical to realizing our vision to transform health outcomes in rural and underserved communities," said Ron Gimbel, PhD, Clemson professor and director of Clemson Rural Health.
  • According to research conducted by Rural and Remote Health , increasing access to clinical trials reduces health disparities in rural areas.
  • "Partnering with Clemson Rural Health is a significant milestone for GRN," said Bruce Holstien, chairman and CEO at GRN.

Passage Bio Reports Second Quarter 2023 Financial Results and Provides Recent Business Highlights

Retrieved on: 
Monday, August 7, 2023
PASG, Central nervous system, Natural history, Dose, GRN, Survival, Glycogen storage disease, Clinical trial, G&A, Research, DSM-IV codes, GM1, AAV, CNS, Administration, Infant, Genetic distance, Patient, Frontotemporal dementia, Weill Cornell Medicine, CSF, Research and development, R, FTD, Safety, Vaccine, Pharmaceutical industry, Cohort

“We continued to make steady progress advancing our lead clinical programs in the second quarter and further improved our financial strength, extending our cash runway into the fourth quarter of 2025.

Key Points: 
  • “We continued to make steady progress advancing our lead clinical programs in the second quarter and further improved our financial strength, extending our cash runway into the fourth quarter of 2025.
  • Additionally, we are thrilled to have already dosed the first patient at Dose 3, demonstrating effective execution across the program.
  • In FTD, we are excited by emerging data from initial treated patients, which indicates translation from preclinical models into the clinic.
  • General and Administrative (G&A) Expenses: G&A expenses were $8.1 million for the quarter ended June 30, 2023, as compared to $13.0 million as of June 30, 2022.

Government of the Republic of Namibia approves entry into pioneering US$10bn Agreement to develop Sub-Saharan Africa's Largest Green Hydrogen Project with Hyphen Hydrogen Energy

Retrieved on: 
Wednesday, May 24, 2023
Hydrogen, Global Gateway, Civil service commission, FIA, GRN, Government, Implementation, Cabinet, Republic, Climate change, GDP, Economic development, Excellency, European Commission, Uranium mining, Renewable energy, EU

WINDHOEK, Namibia, May 24, 2023 /PRNewswire/ -- The Cabinet of the Government of the Republic of Namibia (GRN) has approved entry into an agreement with Hyphen Hydrogen Energy (Hyphen) to govern the development, implementation and operation of sub-Saharan Africa's largest, and its only fully vertically integrated, green hydrogen project.

Key Points: 
  • WINDHOEK, Namibia, May 24, 2023 /PRNewswire/ -- The Cabinet of the Government of the Republic of Namibia (GRN) has approved entry into an agreement with Hyphen Hydrogen Energy (Hyphen) to govern the development, implementation and operation of sub-Saharan Africa's largest, and its only fully vertically integrated, green hydrogen project.
  • At full scale development, anticipated before the end of the decade, the project will produce 2 million tonnes of green ammonia annually.
  • The pioneering Feasibility and Implementation Agreement (FIA) governs the process under which Namibia's first green hydrogen project will be realised, as a first step in the implementation of GRN's broader green hydrogen strategy.
  • On behalf of Hyphen, I would like to thank the Government for its unwavering support and relentless commitment to unlocking Namibia's green hydrogen potential.

Government of the Republic of Namibia approves entry into pioneering US$10bn Agreement to develop Sub-Saharan Africa's Largest Green Hydrogen Project with Hyphen Hydrogen Energy

Retrieved on: 
Wednesday, May 24, 2023
Hydrogen, Global Gateway, Civil service commission, FIA, GRN, Government, Implementation, Cabinet, Republic, Climate change, GDP, Economic development, Excellency, European Commission, Uranium mining, Renewable energy, EU

WINDHOEK, Namibia, May 24, 2023 /PRNewswire/ -- The Cabinet of the Government of the Republic of Namibia (GRN) has approved entry into an agreement with Hyphen Hydrogen Energy (Hyphen) to govern the development, implementation and operation of sub-Saharan Africa's largest, and its only fully vertically integrated, green hydrogen project.

Key Points: 
  • WINDHOEK, Namibia, May 24, 2023 /PRNewswire/ -- The Cabinet of the Government of the Republic of Namibia (GRN) has approved entry into an agreement with Hyphen Hydrogen Energy (Hyphen) to govern the development, implementation and operation of sub-Saharan Africa's largest, and its only fully vertically integrated, green hydrogen project.
  • At full scale development, anticipated before the end of the decade, the project will produce 2 million tonnes of green ammonia annually.
  • The pioneering Feasibility and Implementation Agreement (FIA) governs the process under which Namibia's first green hydrogen project will be realised, as a first step in the implementation of GRN's broader green hydrogen strategy.
  • On behalf of Hyphen, I would like to thank the Government for its unwavering support and relentless commitment to unlocking Namibia's green hydrogen potential.

EQS-News: Greenalia and P2X-Europe join forces to develop an eFuel production project in Galicia

Retrieved on: 
Monday, May 22, 2023
Partnership, Face, R group, GRN, Aviation, H&R, PTL, Wind, Chemical industry, Power, Biomass, CO2, Structural adjustment, Hydrocarbon, Airline, Natural gas, Renewable energy

The initiative envisages a circular process in which, together with green hydrogen, biogenic CO2 would be used to produce the hydrocarbons.

Key Points: 
  • The initiative envisages a circular process in which, together with green hydrogen, biogenic CO2 would be used to produce the hydrocarbons.
  • The CEO of Greenalia, Manuel García, states "this project approaches the process from a circular, global, sustainable and innovative perspective.
  • Through project Breogán, P2X and GRN will strengthen their commitment to the region of Galicia.
  • Already being a leader in renewable energy production, Galicia now has the potential to also become a leader in the production of green molecules such as green hydrogen and synthetic fuels from renewable sources.